Skip to main navigation Skip to search Skip to main content

Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study

  • Michael Mannstadt
  • , Bart L Clarke
  • , Tamara Vokes
  • , Maria Luisa Brandi
  • , Lakshminarayan Ranganath
  • , William D Fraser
  • , Peter Lakatos
  • , Laszlo Bajnok
  • , Roger Garceau
  • , Leif Mosekilde
  • , Hjalmar Lagast
  • , Dolores Shoback
  • , John P Bilezikian

Research output: Contribution to journal › Article › peer-review

283 Citations (Scopus)

Abstract

Hypoparathyroidism results in impaired mineral homoeostasis, including hypocalcaemia and hyperphosphataemia. Treatment with high-dose oral calcium and active vitamin D does not provide adequate or consistent control of biochemical indices and can lead to serious long-term complications. We aimed to test the efficacy, safety, and tolerability of once-daily recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) in adults with hypoparathyroidism.
Original languageEnglish
Pages (from-to)275-283
Number of pages9
JournalThe Lancet Diabetes & Endocrinology
Volume1
Issue number4
Early online date7 Oct 2013
DOIs
Publication statusPublished - 1 Dec 2013

Cite this